Get the Stockscreener App
25.03
5.80%
1.397
Ideaya Biosciences Inc stock is traded at $25.03, with a volume of 1.23M.
It is up +5.80% in the last 24 hours and up +14.78% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$23.63
Open:
$23.83
24h Volume:
1.23M
Relative Volume:
1.05
Market Cap:
$2.19B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-11.43
EPS:
-2.19
Net Cash Flow:
$-134.36M
1W Performance:
+13.17%
1M Performance:
+14.78%
6M Performance:
+5.84%
1Y Performance:
-40.77%
1-Day Range:
$23.57
$25.54
1-Week Range:
$21.33
$25.54
52-Week Range:
$13.45
$44.42
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
25.05 | 1.93B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.92 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.73 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.27 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
587.20 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.89 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
IDEAYA to present phase 2 data on uveal melanoma drug at ESMO By Investing.com - Investing.com South Africa
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma - Yahoo Finance
What drives IDEAYA Biosciences Inc. stock priceRobust financial gains - Autocar Professional
What analysts say about IDEAYA Biosciences Inc. stockFree Investment Portfolio Suggestions - Autocar Professional
IDEAYA Biosciences: Precision Oncology Pipeline and Synthetic Lethality Catalysts - AInvest
IDEAYA's First-in-Class Cancer Pipeline: Major Clinical Updates Coming at 10th Anniversary R&D Day - Stock Titan
Signaturefd LLC Increases Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC - The Malaysian Reserve
Is IDEAYA Biosciences Inc. a good long term investmentRobust financial gains - jammulinksnews.com
IDEAYA Biosciences Inc. Stock Analysis and ForecastHigh-margin investment plays - jammulinksnews.com
Breakthrough Lung Cancer Drug IDE849 Shows First Human Results: 70+ Patient Data Coming at WCLC 2025 - Stock Titan
Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN
IDEAYA Biosciences: TD Cowen initiates coverage with Buy rating. - AInvest
Promising Pipeline and Strategic Focus Drive Buy Rating for IDEAYA Biosciences - TipRanks
TD Cowen initiates Ideaya Biosciences stock with Buy rating By Investing.com - Investing.com Canada
autocarpro> 2025> What analysts say about IDEAYA Biosciences Inc. stockPhenomenal trading returns - Autocar Professional
IDEAYA Biosciences CEO Fireside Chat: Precision Medicine Updates at BTIG Conference - Stock Titan
Teacher Retirement System of Texas Cuts Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
(IDYA) Proactive Strategies - news.stocktradersdaily.com
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionROI Driven Alerts - Newser
How IDEAYA Biosciences Inc. stock performs during market volatilityDaily Stock Radar - Newser
Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Target Price at $47.55 - Defense World
The Goldman Sachs Group Upgrades IDEAYA Biosciences (NASDAQ:IDYA) to “Hold” - Defense World
IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Royal Bank Of Canada - Defense World
Ideaya Biosciences stock gets Neutral rating from Goldman Sachs By Investing.com - Investing.com Canada
Ideaya Biosciences price target lowered to $30 from $57 at RBC Capital - MSN
Ideaya Biosciences shares fall 2.68% intraday as Biocytogen Pharmaceuticals enters into a global licensing agreement with BeOne Medicines. - AInvest
RBC Capital Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
Ideaya Biosciences stock price target lowered to $30 by RBC Capital - Investing.com Canada
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.00%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):